Granules secures FTF status for CNS depressant generic
Granules India has secured sole first-to-file status for a generic version of the narcolepsy drug Lumryz. This achievement marks a significant step in the company's strategy to expand its portfolio of complex generic pharmaceuticals in the U.S. market.
Why it matters
Securing first-to-file status is a major competitive advantage in the pharmaceutical industry, often leading to market exclusivity and increased revenue potential.
Granules India has secured sole first-to-file (FTF) status for its abbreviated new drug application (ANDA) for Sodium Oxybate extended-release for oral suspension, the generic equivalent of Lumryz ER oral suspension of Alkermes plc.
The article is a straightforward business report regarding pharmaceutical regulatory milestones.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in